626 related articles for article (PubMed ID: 26329778)
21. Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma.
Yamada T; Tsuji S; Nakamura S; Egashira Y; Shimazawa M; Nakayama N; Yano H; Iwama T; Hara H
J Neurosurg; 2020 Mar; 134(3):701-710. PubMed ID: 32168477
[TBL] [Abstract][Full Text] [Related]
22. O6-Methylguanine-methyltransferase (MGMT) promoter methylation status in glioma stem-like cells is correlated to temozolomide sensitivity under differentiation-promoting conditions.
Villalva C; Cortes U; Wager M; Tourani JM; Rivet P; Marquant C; Martin S; Turhan AG; Karayan-Tapon L
Int J Mol Sci; 2012; 13(6):6983-6994. PubMed ID: 22837675
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological inhibition of serine synthesis enhances temozolomide efficacy by decreasing O
Jin L; Kiang KM; Cheng SY; Leung GK
Lab Invest; 2022 Feb; 102(2):194-203. PubMed ID: 34625658
[TBL] [Abstract][Full Text] [Related]
24. GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment.
Li J; Cai J; Zhao S; Yao K; Sun Y; Li Y; Chen L; Li R; Zhai X; Zhang J; Jiang C
J Exp Clin Cancer Res; 2016 Nov; 35(1):184. PubMed ID: 27894350
[TBL] [Abstract][Full Text] [Related]
25. The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells.
Clark PA; Gaal JT; Strebe JK; Pasch CA; Deming DA; Kuo JS; Robins HI
J Clin Neurosci; 2017 Feb; 36():120-124. PubMed ID: 27865821
[TBL] [Abstract][Full Text] [Related]
26. IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide.
Natsume A; Ishii D; Wakabayashi T; Tsuno T; Hatano H; Mizuno M; Yoshida J
Cancer Res; 2005 Sep; 65(17):7573-9. PubMed ID: 16140920
[TBL] [Abstract][Full Text] [Related]
27. NEO212, temozolomide conjugated to perillyl alcohol, is a novel drug for effective treatment of a broad range of temozolomide-resistant gliomas.
Cho HY; Wang W; Jhaveri N; Lee DJ; Sharma N; Dubeau L; Schönthal AH; Hofman FM; Chen TC
Mol Cancer Ther; 2014 Aug; 13(8):2004-17. PubMed ID: 24994771
[TBL] [Abstract][Full Text] [Related]
28. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM
Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773
[TBL] [Abstract][Full Text] [Related]
29. MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas.
Oldrini B; Vaquero-Siguero N; Mu Q; Kroon P; Zhang Y; Galán-Ganga M; Bao Z; Wang Z; Liu H; Sa JK; Zhao J; Kim H; Rodriguez-Perales S; Nam DH; Verhaak RGW; Rabadan R; Jiang T; Wang J; Squatrito M
Nat Commun; 2020 Aug; 11(1):3883. PubMed ID: 32753598
[TBL] [Abstract][Full Text] [Related]
30. Investigating a signature of temozolomide resistance in GBM cell lines using metabolomics.
St-Coeur PD; Poitras JJ; Cuperlovic-Culf M; Touaibia M; Morin P
J Neurooncol; 2015 Oct; 125(1):91-102. PubMed ID: 26311249
[TBL] [Abstract][Full Text] [Related]
31. Disulfiram sensitizes pituitary adenoma cells to temozolomide by regulating O6-methylguanine-DNA methyltransferase expression.
Zhao Y; Xiao Z; Chen W; Yang J; Li T; Fan B
Mol Med Rep; 2015 Aug; 12(2):2313-22. PubMed ID: 25937029
[TBL] [Abstract][Full Text] [Related]
32. Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression.
Lan F; Yang Y; Han J; Wu Q; Yu H; Yue X
Int J Oncol; 2016 Feb; 48(2):559-68. PubMed ID: 26648123
[TBL] [Abstract][Full Text] [Related]
33. Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo.
Yu Z; Zhao G; Xie G; Zhao L; Chen Y; Yu H; Zhang Z; Li C; Li Y
Oncotarget; 2015 Oct; 6(32):32930-43. PubMed ID: 26431379
[TBL] [Abstract][Full Text] [Related]
34. Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation.
Nguyen SA; Stechishin OD; Luchman HA; Lun XQ; Senger DL; Robbins SM; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Sep; 20(18):4894-903. PubMed ID: 25078279
[TBL] [Abstract][Full Text] [Related]
35. Gene expression profiling predicts response to temozolomide in malignant gliomas.
Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E; Tsumoto K
Int J Oncol; 2010 Jun; 36(6):1367-77. PubMed ID: 20428759
[TBL] [Abstract][Full Text] [Related]
36. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M
J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110
[TBL] [Abstract][Full Text] [Related]
37. Gene expression profiles predicting the response to IFN-β and a combination of temozolomide and IFN-β in malignant gliomas.
Yoshino A; Tashiro S; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Sano E; Tsumoto K
Int J Oncol; 2011 Sep; 39(3):529-42. PubMed ID: 21805051
[TBL] [Abstract][Full Text] [Related]
38. O6-methylguanine-DNA methyltransferase is downregulated in transformed astrocyte cells: implications for anti-glioma therapies.
Sasai K; Akagi T; Aoyanagi E; Tabu K; Kaneko S; Tanaka S
Mol Cancer; 2007 Jun; 6():36. PubMed ID: 17547775
[TBL] [Abstract][Full Text] [Related]
39. Givinostat Inhibition of Sp1-dependent MGMT Expression Sensitizes Glioma Stem Cells to Temozolomide.
Nakagawa-Saito Y; Mitobe Y; Togashi K; Suzuki S; Sugai A; Kitanaka C; Okada M
Anticancer Res; 2023 Mar; 43(3):1131-1138. PubMed ID: 36854532
[TBL] [Abstract][Full Text] [Related]
40. MiR-198 enhances temozolomide sensitivity in glioblastoma by targeting MGMT.
Nie E; Jin X; Wu W; Yu T; Zhou X; Shi Z; Zhang J; Liu N; You Y
J Neurooncol; 2017 May; 133(1):59-68. PubMed ID: 28425046
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
